On the stock market since 2004, it operates in the world of health and science. It has 159 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
No real growth (2% a year).
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Debt is low and cash is strong; the finances stand solid.
The price looks reasonable next to what the company earns.
Sales are growing strongly for its sector.
The price is looking for direction — no strong breakout, no collapse.
No real weak spot in any of the five subjects — a balanced report card.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades below its recent peak — about 10% off the top. A pullback, not a collapse.
The net profit margin is 64% — still a thick cushion, though costs have been eating into it lately.
Over the last 3 years, sales grew about 9% a year on average.
There is $550.9M in the vault; even if every debt were paid off, $281.9M would remain.
The price action doesn’t yet back an upward turn. Council score: 0/10.
On our five-subject report card, INVA sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: INVA is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.